Aim: We aimed to investigate EWI-2 expression in endometrium tissues collected from women with endometriosis at mRNA and protein levels, to evaluate its potential as a biomarker for endometriosis and to study its functional role via possible regulation of the PI3K/Akt signaling pathway. Methods: Endometrium tissues were collected from patients with endometriosis and healthy individuals. EWI-2 mRNA expression was evaluated using quantitative real-time PCR (qRT-PCR) while EWI-2 protein levels were determined by western blotting. For functional studies, EWI-2 shRNA was transfected in endometrial epithelial cells and the in vitro migration and invasion assays were performed using the Transwell chambers. Results: EWI-2 was significantly downregulated in tissues obtained from patients with endometriosis compared with healthy individuals (P < 0.0001). EWI-2 expression in the secretory phase was lower than that in the proliferative phase (P < 0.0001). Receiver-operator curve analysis of EWI-2 expression showed that the area under the curve for endometriosis diagnosis was 0.8942 (P = 0.003), 0.9643 (P = 0.0001), 0.9912 (P < 0.0001), and 0.9150 (P < 0.0001), respectively, for healthy women compared with women with endometriosis in matched comparisons of data originated from the proliferative, early, middle, and late secretory phases. Over the menstrual cycle, the expression of EWI-2 was significantly decreased in the eutopic tissues compared to the ectopic tissues. Further cellular and molecular analyses showed that EWI-2 inhibited cell migration and invasion via the Akt signaling. Conclusion: Our findings suggested that downregulation of EWI-2 may contribute to endometriosis physiopathology and potentiate EWI-2 as a valuable diagnostic biomarker and therapeutic target for endometriosis.
Introduction
Endometriosis, characterized by the growth of endometrial cells in other areas of the body, is a poorly studied chronic gynecological disease that affects women of reproductive age and causes a multitude of symptoms, including dyspareunia, infertility, and persistent pain in the pelvic area. [1] [2] [3] [4] The incidence of endometriosis in women is estimated to be about 10% and counts for 20-v90% in female patients with pelvic pain or infertility. 1 Although substantial improvement has been made in our understanding of the physiopathology of endometriosis, its etiology and the underlying pathophysiology are still largely unknown. 1 In addition, the current tools used in the diagnosis of endometriosis are invasive and effective therapy options for this disease are limited. 5, 6 Therefore, researchers are attempting to develop non-invasive biomarkers, including proteinbased and microRNA-based biomarkers, [7] [8] [9] for the diagnosis and directed therapy of endometriosis.
EWI-2, the immunoglobulin superfamily member 8 (IGSF8), has been previously reported to play a functional role in fertilization 10, 11 and sperm-oocyte fusion. 12 Previous research has equally shown that EWI-2 can negatively regulate cell proliferation, invasion, motility and filopodia formation. [13] [14] [15] In addition, the overexpression of EWI-2 has been reported to inhibit glioblastoma cell growth and migration and is therefore considered as a potential therapeutic target in human glioma. 16 Recently, studies have analogously conveyed that EWI-2 inhibits melanoma growth and metastasis by targeting the transforming growth factor (TGF)-β signaling. 17, 18 These inhibitory effects of EWI-2 on cancer cells suggest that EWI-2 may similarly play a functional role in the pathogenesis of endometriosis and could constitute a potential therapeutic target for this disease. Nevertheless, the expression of EWI-2 during the menstrual cycle and, especially, endometriosis, has not been scrutinized so far. Furthermore, the molecular mechanisms underlying the potential function of EWI-2 in endometriosis are unknown and yet to be clarified.
Therefore, in this study, we aimed to evaluate the expression of EWI-2 in endometriosis and to investigate the effects of EWI-2 on migration, proliferation, and invasion of endometrial epithelial cells for providing insight into its role in the pathogenesis of this disease and the underlying molecular mechanisms.
Methods

Patients and tissue collection
We collected human endometrial tissues from the Reproductive Medicine Center at Renmin Hospital of Wuhan University. The study was approved by the institutional ethical review board of Renmin Hospital of Wuhan University. Informed consent was obtained from subjects before their inclusion in the study. For the determination of EWI-2 expression, samples were collected from 145 women (aged 21-48 years old) with a regular menstrual cycle using the Novak curette during laparoscopy. Subjects were distributed into two groups: the control group (n = 67, laparoscopically negative) and the deep ovarian endometriosis (endometrioma) group (n = 76, laparoscopically positive). The phase of the menstrual cycle was ascertained taking into account the last menstrual date and the amounts of reproductive hormones. The patients with endometriosis and healthy individuals were distributed according to the menstrual cycle. For the patients, the distribution for the determination of EWI-2 expression according to the menstrual cycle was as follows: n = 14 for the proliferative phase; n = 13 for the early secretory phase; n = 17 for the middle secretory phase; and n = 17 for the late secretory phase. For determination of EWI-2 expression in eutopic and ectopic tissues, patient distribution was as follows: n = 22 for the proliferative phase; n = 22 for the early secretory phase; n = 20 for the middle secretory phase; and n = 14 for the late secretory phase. For the healthy individuals, the number of individuals in each menstrual cycle phase was: n = 16 for the proliferative phase; n = 13 for the early secretory phase; n = 20 for the middle secretory phase; and n = 18 for the late secretory phase. Women medicated for hormonal or IUD treatment during the 3 months preceding the surgical intervention were categorically excluded from the study. The criteria of Noyes et al. 19 were used for histologic dating of endometrial samples, which was validated via histopathological examination by two different qualified pathologists.
Cell culture
Endometrial epithelial cells (EEC) were isolated from normal endometrial tissues as described elsewhere, 20 seeded onto Primaria culture flasks in phenol red-free DMEM/F-12 containing 100 U/mL penicillin, 10% Fetal bovine serum (FBS), and 0.25 μg/mL amphotericin B plus 0.1 mg/mL streptomycin, and incubated at 37°C in 95% air/5% CO2. After incubation for 1 h, EEC were dissociated and re-cultured until confluence after 2-3 days. The first passages were employed in the experiments. The purity of isolated EEC was checked by immunofluorescent staining using monoclonal antibodies against human vimentin (V9, 1:100, DAKO), cytokeratin (MNF116, 1:100, DAKO), CD 45 (1:100, DAKO), and factor VIII (1:100, DAKO).
Transient transfection
For quantitative real-time PCR (qRT-PCR), cells, at a density of 50 000 cells/well, were cultured using 24-well plates, whereas 60-mm dishes (200 000 cells per dish) were used for western blot analysis. Cells were seeded in serum-free OPTI-MEM for 24 h prior to transfection. The construction of the vector used for EWI-2 expression and transfection in EEC was as described previously. 21 For stable knockdown, lentiviral plasmids containing EWI-2 shRNAs (human EWI-2 [RHS4533-EG93185, RHS4531-EG93185] purchased from Open Biosystems) were purified and transfected together with pCMVdR8.91 and VSV-G plasmids into isolated EEC using lipofectamine 2000. Medium containing lentivirus was collected after 48 h and 72 h and used for the transfection Differential expression of EWI-2 of cells for 12 h. Stable cells were selected with 5 μg/mL puromycin (Invitrogen).
Cell proliferation assays
Cell proliferation assay was achieved by means of a Cell Counting Kit 8 (CCK-8) (Dojindo Laboratories). Briefly, cells were cultured into 96-well plates (10 000 cells/well) containing 10% FBS and incubated for 24 h. Next, FBS was replaced with serum free medium and untransfected, control shRNA-and EWI-2 shRNAtransfected cells were incubated at 37°C at 5% CO2 for 72 h. After that, CCK-8 solution (10 μL) was put into each well, and incubated at 37°C for an extra 2 h. Optical density was examined at a wavelength of 450 nm.
In vitro migration and invasion assays
The determination of cell invasion and migration was achieved in vitro using uncoated or Matrigel-coated invasion chambers and microfilters (Becton Dickinson). Briefly, after rehydration of the chambers, cells were seeded in 500 μL phenol red-free DMEM/F12 short of FBS (Life Technologies) in the superior chamber while 750 μL phenol red-free DMEM/F12 supplemented with 10% FBS (Life Technologies) were added in the lower chamber. Cells were left for migration for 24 h in terms of which cell migration was determined as the amount of cells that migrated from a distinct region of the uncoated microfilter within micropores. Similarly, cell invasion was expressed as the quantity of invasive cells from a defined area of the Matrigel-coated microfilter through micropores in 24 h. All the experiments were done in triplicate. The micropore filters were dyed with toluidine blue, and the quantity of cells that migrated across filters was enumerated in the whole surface of each filter. To count cell numbers objectively, a light microscope (40X-1000X Biological Science Student Compound Microscope, SKU: M102C-PB10, AmScope Company) was used.
RNA extraction and qRT-PCR detection of EWI-2 expression
Total RNA was isolated with TRIzol (Invitrogen) from isolated EEC or frozen endometrium samples of healthy women and women with endometriosis. Subsequently, 1.5 μg extracted total RNA was converted into cDNA using First-Strand Synthesis System for qRT-PCR (Invitrogen). The qRT-PCR experiment was achieved with the QuantiFast SYBR Green PCR Kit (Qiagen) according to the vendor's procedure using a reaction volume of 20 μL. The PCR cycling condition was set as 
Western blot analysis
One hundred micrograms of proteins were extracted from the EEC of healthy women and the endometrial tissues of healthy women and subjects with endometriosis and analyzed by 10% acrylamide gel SDS-PAGE, followed by electrotransfer onto a nitrocellulose membrane. After blocking the membrane in 5% skim milk powder in 0.1% Tris-buffered saline/Tween for 20 min, the membrane was subsequently incubated with primary antibodies against
, and integrin β2 (anti-Integrin β2 [CD18] Antibody [CBL158], Merck Millipore) at a dilution of 1:1000 overnight at 4°C. After that, the membranes were washed thrice and then incubated with HRP-conjugated secondary antibody. All the antibodies were purchased from ABCAM unless otherwise indicated. GAPDH was used as a housekeeping gene. The blotting bands were developed with ECL plus immunoblotting detection reagents.
Evaluation and statistical analysis
Data are presented as mean ± standard deviation (SD). The t-test and one-way analysis of variance, followed by Bonferroni post-test for comparison of all pairs of groups for each studied parameter, and receiveroperator curve (ROC) analysis were performed using Graph Pad Prism version 6 for Windows, GraphPad Software (www.graphpad.com).
Results
EWI-2 expression in endometrium samples of women with and without endometriosis and evaluation of its diagnostic accuracy
To investigate EWI-2 expression pattern in endometriosis, endometrial tissues were collected at each phase of the menstrual cycle and examined for mRNA and protein levels by qRT-PCR and western blotting, respectively. The qRT-PCR results (Fig. 1) showcased the effective EWI-2 expression in the endometrial tissues. No significant difference was found between the proliferative and secretory phases of the menstrual cycle in samples collected from healthy women. Compared to control samples, EWI-2 expression was significantly (P < 0.0001) decreased in samples collected from women with endometriosis. In addition, in tissues from women with endometriosis, EWI-2 expression was decreased in the secretory phase compared to the proliferative phase. The relative EWI-2 protein levels obtained from western blot analysis were corroborated with those obtained from the qRT-PCR results.
To analyze the potential role of EWI-2 as a diagnostic marker for endometriosis, ROC analysis was applied to the above EWI-2 mRNA expression data. As shown in Figure 2 , ROC analysis showed that the AUC values for endometriosis diagnosis were 0.8942 (P = 0.003), 0.9643 (P = 0.0001), 0.9912 (P < 0.0001), and 0.9150 (P < 0.0001), respectively, for healthy women compared with women with endometriosis in matched comparisons of data originated from the proliferative, early, middle, and late secretory phases. These results suggest that EWI-2 could be a biomarker and therapeutic target for endometriosis. 
EWI-2 expression in stage-matched eutopic and ectopic endometria from women with endometriosis
To examine the expression of EWI-2 in stage-matched eutopic (EU) and ectopic (EC) tissues of women with endometriosis, we performed qRT-PCR and western blotting experiments. The results (Fig. 3) showed that EWI-2 was decreased in EU tissues at mRNA and protein levels were compared to the EC tissues in both the proliferative and the secretory phases of the menstrual cycle. Compared to results depicted in Figure 1 , EWI-2 gene expression was significantly higher in control endometrium of healthy women. This expression decreased from control to lesions and eutopic endometrium, respectively.
EWI-2 inhibits endometrial epithelial cell migration and invasion
To examine the biological functions of EWI-2 in endometrial epithelial cells, we performed cell invasion and migration assays. The results showed that after EWI-2 knockdown, the migratory and invasive abilities of EEC were significantly increased (Fig. 4a,b) . CCK-8 assay (Fig. 4c) revealed that EWI-2 knockdown did not significantly affect the viability of EEC. These results implied that EWI-2 inhibits migration and invasion of EEC.
EWI-2 inhibits expression of invasion-and migration-related genes in EEC via PI3K/Akt signaling
Western blot analysis of invasion-and migration-related genes in EEC showed that Rac1, CD9, integrin β2, MMP9, Myd88, and Notch1 were upregulated following EWI-2 knockdown compared to the untransfected cells (Fig. 5a,b) . Akt signaling plays critical roles in the migration and invasion of endometrial cells. [22] [23] [24] To assess the role of Akt activation in the inhibition of EEC migration and invasion, we performed western blot analyses in order to determine the effect of EWI-2 on Akt phosphorylation and found that EWI-2 knockdown increased AKT phosphorylation (Fig. 5a,b) . In contrast, forcibly expressing EWI-2 in EEC led to decreased AKT phosphorylation. Similarly, simultaneous EWI-2 knockdown and PI3K inhibition led to decreased AKT phosphorylation whereas concomitant inhibition of PI3K and forced expression of EWI-2 resulted in significant AKT activation. These results indicated that EWI-2 downregulation contributes to AKT activation and overexpression of EWI-2 inhibits this activation. To further understand if the negative regulation of AKT by EWI-2 participates in cell invasion and migration, we measured the expression of invasion and migration markers in different cell groups and treatments. We found that forced EWI-2 expression decreased the expression of Rac1, CD9, integrin β2, MMP9, Myd88, and Notch1 at both the mRNA and protein levels (Fig. 5a,b) . The inverse trend was found after Akt inhibition and forced expression of EWI-2. These observations implied that EWI-2 inhibits the migration and invasion of EEC via negative regulation of the PI3K/Akt axis.
Discussion
EWI-2, widely expressed in the peripheral blood lymphocytes, brain, and hepatocytes, is a cell surface immunoglobulin SF protein that has been reported to be involved in the physiopathology of various diseases, especially cancers, and in different biological processes, including fertilization, cell migration, and cell invasion. 10, [12] [13] [14] [15] [16] [17] [18] [19] 25 Nonetheless, the biological role of EWI-2 in endometriosis has not been investigated so far. Due to the pathophysiological similarities of endometriosis with carcinoma, especially in terms of cell migration and invasion, we assumed that EWI-2 could play a crucial role in physiological homeostasis in the regular menstrual cycle. We equally hypothesized that EWI-2 expression could be altered in endometriosis, which implies its potential role in the physiopathology of this disease. Herein, we measured the expression of EWI-2 in endometrial tissues of women with endometriosis across the menstrual cycle at mRNA and protein levels using qRT-PCR and western blot analyses, and found that EWI-2 was dramatically downregulated in endometrial tissues obtained from women with endometriosis compared to the levels obtained from the endometrium of healthy patients. ROC analysis showed that EWI-2 could be a potential biomarker for discriminating between healthy women and women with endometriosis. To the best of our knowledge, this study is the first to report decreased expression of EWI-2 in endometriosis.
In addition, while no significant difference was found between the proliferative and secretory phases of the menstrual cycle in tissues collected from healthy women, in tissues from women with endometriosis, EWI-2 levels were decreased in the secretory phase compared to the proliferative phase. This observation suggested that EWI-2 is probably involved in the regulation of the menstrual cycle in the endometrium of women with endometriosis. We also found that the expression of EWI-2 in ectopic tissue was greater when compared to the eutopic endometrium of patients with endometriosis. These results suggest that EWI-2 downregulation is possibly involved in the initiation processes of endometriosis and were in conformity with the conventional theory that cellular dysfunction at the eutopic site may confer ability for implantation and lesion formation after retrograde menstruation. 26 Similarly, the deregulation at ectopic sites is supposedly essential for facilitating the early process of lesion implantation. 27 Thus, the decreased expression of EWI-2 in endometriotic tissues compared with the normal endometrium and the differential expression between the eutopic and ectopic sites suggested that EWI-2 may play essential functions in endometriosis.
The definite function of EWI-2 in endometriosis is unknown. Nonetheless, based on previous reports on the role of EWI-2 in other diseases, [16] [17] [18] we stipulated that this protein might be intrinsically correlated with cell invasion or migration in the pathophysiology of endometriosis. Indeed, the activation of cell migration and invasion are the main processes occurring in endometriosis. 28, 29 To further verify our hypothesis on the probable involvement of EWI-2 in these processes, we knocked down the EWI-2 gene in EEC using EWI-2 shRNA and performed cell migration and invasion assays. Our results showed that knockdown of EWI-2 increased cell migration and invasion while the forced expression of EWI-2 reversed these effects, which indicated that EWI-2 inhibits the migration and invasion of EEC. This finding was in corroboration with the results of previous studies demonstrating the role of EWI-2 in the migration, invasion, adhesion, aggregation, and metastasis of cancer cells. 12, [14] [15] [16] [17] [18] [19] 25 This was further confirmed by the downregulation of proteins involved in cell migration and invasion, namely Rac1, CD9, integrin β2, MMP9, Myd88, and Notch1. The greater expression of EWI-2 in ectopic endometrial tissues when compared with the eutopic endometrial tissues indicated that the migration and invasion of eutopic endometrial cells may be more active than the ectopic endometrial cells in patients with endometriosis. Furthermore, the decreased expression of EWI-2 in the secretory phase suggested that endometriosis may be more severe during the secretory phase of the menstrual cycle, which may favor increased cell migration and invasion to subsequently influence implantation dysfunctions and thus endometriosisassociated infertility. This result also indicated that EWI-2 is probably involved in endometrial dysfunctions in patients with endometriosis and in regulatory mechanisms underlying the pathophysiology of endometriosis. AKT signaling hyperactivation is characteristic of almost all human malignancies. [30] [31] [32] [33] In this study, we found that EWI-2 overexpression led to downregulated expression of invasion and migration markers via inhibition of PI3K/Akt signaling. This is the first evidence of probable EWI-2/PI3K/Akt cross-talk in endometriosis. The study gives new insights into the molecular mechanism of EWI-2 in cell invasion and migration. The previously reported mechanisms indicate that EWI-2 regulates cell functions by controlling the expression of α3β1, 13 TGF-β signaling, 17 or co-regulating KAI1/CD82 by association with PGRL.
14 Our findings corroborated with those of other researchers who indicated that activation of PI3K/Akt signaling is involved in pathological and physiological processes of endometrial cells.
Conclusion
EWI-2 is significantly downregulated in endometriosis and could constitute a potential biomarker and therapeutic target for endometriosis treatment. We equally demonstrated that EWI-2 exerts its protective effects by inhibiting cell invasion and migration through Akt signaling.
